SCHEMBL12890779

SCHEMBL12890779

CC(C)[C@H](NC(=O)OC(C)(C)C)C(=O)NC(CCc1cccc(NC(=NC(=O)OC(C)(C)C)NC(=O)OC(C)(C)C)c1)C(=O)O

nearest known ligand 0.42

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
▸ CTSS P25774 1/20 0.41
▸ CTSK P43235 1/20 0.41
▸ HDAC4 P56524 2/20 0.41
▸ HDAC1 Q13547 2/20 0.41
▸ MEN1 O00255 1/20 0.41
▸ KMT2A Q03164 1/20 0.41
▸ ATM Q13315 1/20 0.41
▸ HDAC3 O15379 1/20 0.40
▸ HDAC7 Q8WUI4 1/20 0.40
▸ HDAC2 Q92769 1/20 0.40
▸ HDAC10 Q969S8 1/20 0.40
▸ HDAC11 Q96DB2 1/20 0.40
▸ HDAC8 Q9BY41 1/20 0.40
▸ HDAC6 Q9UBN7 1/20 0.40
▸ HDAC9 Q9UKV0 1/20 0.40
▸ HDAC5 Q9UQL6 1/20 0.40
▸ BACE1 P56817 5/20 0.38
▸ BACE2 Q9Y5Z0 1/20 0.38
▸ GLS O94925 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12890783 0.91 CTSS (0.40) CTSSCTSKHDAC4HDAC1HDAC3
SCHEMBL12890778 0.86 HDAC4 (0.38) CTSSCTSKHDAC4HDAC1HDAC3
SCHEMBL31407307 0.78 CTSK (0.55) CTSSCTSKHDAC4HDAC1HDAC3
SCHEMBL7131891 0.78 PSMB5 (0.40) CTSSCTSKHDAC4HDAC1MEN1
SCHEMBL12891391 0.76 LTA4H (0.42) HDAC4HDAC1BACE1
SCHEMBL207904 0.76 PDK1 (0.47) HDAC4HDAC1HDAC3HDAC7HDAC2
SCHEMBL7133761 0.75 PSMB5 (0.36) CTSSCTSKHDAC4HDAC1MEN1
SCHEMBL31250549 0.74 CTSK (0.41) CTSSCTSKHDAC4HDAC1HDAC3
SCHEMBL8130179 0.72 KMT2A (0.67) CTSSCTSKMEN1KMT2AATM
SCHEMBL29602242 0.72 KMT2A (0.67) CTSSCTSKMEN1KMT2AATM

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7879795-B2 can be coadministered with antimicrobial agents for treatment of infections caused by drug resistant bacteria; 2-Amino-N-{4-Amino-1-[-3-phenyl-1-(R)-(quinolin-3-ylcarbomoyl)-propylcarbamoyl]-butyl}succinamic acid; 2,5-Diamino-pentanoic acid [3-phenyl-1-(R)-(4-phenyl-thiazol-2-ylcarbamoyl)-propyl]-amide MPEX PHARMACEUTICALS, INC. (US) 2011-02-01 — — US disclosed
US-20080076741-A1 ENHANCEMENT OF TIGECYCLINE POTENCY USING EFFLUX PUMP INHIBITORS REMPEX PHARMACEUTICALS, INC. 2008-03-27 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080076741-A1 ENHANCEMENT OF TIGECYCLINE POTENCY USING EFFLUX PUMP INHIBITORS ABCB1, ABCB11, SLC47A2 CTSS 1133/4885CTSK 1235/4885HDAC4 337/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback